Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Nancy Wainman"'
Autor:
C. A. Capier, John Lyons, Karen A. Gelmon, Kim N. Chi, Lesley Seymour, Nancy Wainman, Derek J. Jonker, Susan Dent, Eric X. Chen
Publikováno v:
Investigational New Drugs. 31:1522-1529
Purpose AT9283 is a potent inhibitor of the mitotic regulators, Aurora-kinases A and B, and has shown anti-tumor activity in patients with solid and haematological malignancies. This phase I study assessed safety, tolerability, pharmacokinetic and ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49d50baab085085412f61fc3d51fb345
https://doi.org/10.1007/s10637-013-0018-9
https://doi.org/10.1007/s10637-013-0018-9
Autor:
Mark L. Bernstein, Sylvain Baruchel, Darcy Nicksy, Yvan Samson, Elizabeth Eisenhauer, Alexandra P. Zorzi, Nancy Wainman, Sunil Desai, Donna A. Wall
Publikováno v:
Pediatric Blood & Cancer. 60:1868-1874
Background Pracinostat (SB939) is a potent oral inhibitor of class 1, 2, and 4 histone deacetylases (HDAC). The adult recommended phase II dose (RP2D) is 60 mg po three times per week (t.i.w.) for 3 weeks every 4 weeks. This study assessed the toxici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::453f2e509536aca94614b9f77b70362a
https://doi.org/10.1002/pbc.24694
https://doi.org/10.1002/pbc.24694
Phase II Trial of SarCNU in Malignant Glioma: Unexpected Pulmonary Toxicity with a Novel Nitrosourea
Autor:
James Perry, Stan Gertler, Gregory Cairncross, Marc Webster, Elizabeth Eisenhauer, Nancy Wainman
Publikováno v:
Investigational New Drugs. 23:591-596
A multi-centre phase II study of SarCNU-a novel chloroethylnitrosourea (CNU)-in patients with recurrent malignant glioma to assess response rate, survival and effects of treatment.Ten patients with histologically proven malignant glioma (seven with g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31751b10e846db03602c810111e14e91
https://doi.org/10.1007/s10637-005-1761-3
https://doi.org/10.1007/s10637-005-1761-3
Autor:
Ian Quirt, Reinhard Lohmann, Elizabeth Eisenhauer, Wendy Walsh, Richard Tozer, Susan Burdette-Radoux, Nancy Wainman, A. Dimitrios Colevas, D. Scott Ernst
Publikováno v:
Investigational New Drugs. 22:315-322
Purpose: To test the activity of the cyclin dependent kinase (cdk) inhibitor flavopiridol in malignant melanoma, a disease with frequent abnormalities of the cyclin dependent kinase system. Patients and methods: Patients had histologically proven, un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0648d7c22f7022e0964c438099b6f58e
https://doi.org/10.1023/b:drug.0000026258.02846.1c
https://doi.org/10.1023/b:drug.0000026258.02846.1c
Autor:
Nancy Wainman, Gregory Cairncross, Karl Belanger, Samuel K. Ludwin, Elizabeth Eisenhauer, David R. Macdonald, Stan Z. Gertler, Peter A. Forsyth, Susan Burdette-Radoux, Julie Bergeron, Denis Soulières
Publikováno v:
Investigational New Drugs. 21:473-480
To determine the efficacy and toxicity of a novel chemotherapeutic approach with topotecan, a camptothecin analog, for progressive or recurring anaplastic oligodendroglioma or mixed oligoastrocytoma.Patients from seven centers with recurrent or progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::223cdf241f0e8ec83b5ac21f67b650b3
https://doi.org/10.1023/a:1026211620793
https://doi.org/10.1023/a:1026211620793
Autor:
M. Maclean, Nisha Mistry, J. M. Besterman, Debbie Ayers, Susan D'Aloisio, Carolyn D. Britten, Nancy Wainman, Elizabeth Eisenhauer, Henry Klamut, Malcolm J. Moore, Patricia S. Firby, Lillian L. Siu, Alison Davis, Karen A. Gelmon, Gregory K. Reid
Publikováno v:
Investigational New Drugs. 21:85-97
Purpose: MG98 is a second generation phosphorothioate antisense oligodeoxynucleotide which is a highly specific inhibitor of translation of the mRNA for human DNA MeTase I (DNMT 1). This phase I study examined the toxicity and pharmacologic profile o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b90c7758b9714e4d718f4928ed82709e
https://doi.org/10.1023/a:1022976528441
https://doi.org/10.1023/a:1022976528441
Autor:
Vincent Young, William Steward, Nancy Wainman, Elizabeth Eisenhauer, Reinhard Lohmann, Karl Belanger, Ian Quirt, James J. Rusthoven, Audley Bodurtha
Publikováno v:
Investigational New Drugs. 20:431-437
To determine the tolerability and efficacy of daily oral marimastat (BB-2516 in patients with metastatic melanoma and to determine the matrix metalloproteinase (MMP) activity, tumour necrosis, peri- and intra-tumoral fibrosis and tumor inflammation i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da908946e1717c9133d25d7ba3a0c73c
https://doi.org/10.1023/a:1020625423524
https://doi.org/10.1023/a:1020625423524
Autor:
Alexandra P, Zorzi, Mark, Bernstein, Yvan, Samson, Donna A, Wall, Sunil, Desai, Darcy, Nicksy, Nancy, Wainman, Elizabeth, Eisenhauer, Sylvain, Baruchel
Publikováno v:
Pediatric bloodcancer. 60(11)
Pracinostat (SB939) is a potent oral inhibitor of class 1, 2, and 4 histone deacetylases (HDAC). The adult recommended phase II dose (RP2D) is 60 mg po three times per week (t.i.w.) for 3 weeks every 4 weeks. This study assessed the toxicities and ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::22d4921ec1c4d1af63c0a08f007d6792
https://pubmed.ncbi.nlm.nih.gov/23893953
https://pubmed.ncbi.nlm.nih.gov/23893953
Autor:
Antonio Grillo-Lopez, Lloyd R. Whitfield, Jacques Jolivet, Karl Belanger, David J. Stewart, Jean A. Maroun, Nancy Wainman, Elizabeth Eisenhauer
Publikováno v:
Investigational New Drugs. 11:301-308
DUP-937 is a new anthrapyrazole intercalator that inhibits DNA synthesis. A phase I trial was conducted in which DUP-937 was given in an intravenous bolus weekly for 3 weeks. Cycles were repeated every 5 weeks. Twenty men and 13 women with median ECO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f25f58907537e710bbdb3cb06537321
https://doi.org/10.1007/bf00874428
https://doi.org/10.1007/bf00874428
Autor:
Ron Feld, C. Cripps, James Joseph Biagi, Timothy W. Synold, Jennifer J. Knox, Lesley Seymour, Pierre Major, Sharlene Gill, Nancy Wainman, Elizabeth Eisenhauer
Publikováno v:
Investigational new drugs. 26(3)
Hepatocellular carcinoma (HCC) remains a lethal treatment-resistant cancer with a median survival of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e67197d518774efe4c2b1ab274de1140
https://pubmed.ncbi.nlm.nih.gov/18196204
https://pubmed.ncbi.nlm.nih.gov/18196204